Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Phase II, Randomized, Placebo-Controlled Study of Minocycline for Reducing Symptom Burden in Patients With Colorectal Cancer
Status: Enrolling
Updated:  4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Phase II, Randomized, Placebo-Controlled Study of Minocycline for Reducing Symptom Burden in Patients With Colorectal Cancer
Status: Enrolling
Updated: 4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
EvergreenHealth Medical Center
mi
from
Kirkland, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
EvergreenHealth Medical Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Olympic Medical Center
mi
from
Port Angeles, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Olympic Medical Center
mi
from
Port Angeles, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Group Health Cooperative
mi
from
Redmond, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Group Health Cooperative
mi
from
Redmond, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  4/11/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 4/11/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
Northwestern University
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
Veterans Affairs Medical Center - Lakeside Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated:  4/11/2018
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Status: Enrolling
Updated: 4/11/2018
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
LORETA (Low Resolution Electromagnetic Tomography) Neurofeedback
Neurofeedback for Acute Radiotherapy-Induced Pain in Head and Neck Cancer Patients
Status: Enrolling
Updated:  4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
LORETA (Low Resolution Electromagnetic Tomography) Neurofeedback
Neurofeedback for Acute Radiotherapy-Induced Pain in Head and Neck Cancer Patients
Status: Enrolling
Updated: 4/11/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
HELP Prevent Cancer Pilot Study
Healthy Living Partnerships to Prevent Cancer (HELP PC) Pilot Study
Status: Enrolling
Updated:  4/11/2018
Danville Regional Medical Center
mi
from
Danville, VA
HELP Prevent Cancer Pilot Study
Healthy Living Partnerships to Prevent Cancer (HELP PC) Pilot Study
Status: Enrolling
Updated: 4/11/2018
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Greater Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Women's Cancer Center
mi
from
Palo Alto, CA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Women's Cancer Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Colorado Cancer Center
mi
from
Denver, CO
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Colorado Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Walter Reed Army Medical Center
mi
from
Washington,
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Emory University Hospital - Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Medical College of Georgia Comprehensive Cancer Center
mi
from
Augusta, GA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Medical College of Georgia Comprehensive Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
MBCCOP - Hawaii
mi
from
Honolulu, HI
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
MBCCOP - Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Evanston
mi
from
Evanston, IL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Evanston
mi
from
Evanston, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP, Central Illinois
mi
from
Springfield, IL
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP, Central Illinois
mi
from
Springfield, IL
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Albert B. Chandler Medical Center, University of Kentucky
mi
from
Lexington, KY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Albert B. Chandler Medical Center, University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Medicine Branch
mi
from
Bethesda, MD
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Medicine Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Radiation Oncology Branch
mi
from
Bethesda, MD
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Radiation Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Ann Arbor Regional
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Kansas City
mi
from
Kansas City, MO
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
Cancer Center of Albany Medical Center
mi
from
Albany, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
Cancer Center of Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated:  4/11/2018
State University of New York Health Science Center at Brooklyn
mi
from
Brooklyn, NY
Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Status: Enrolling
Updated: 4/11/2018
State University of New York Health Science Center at Brooklyn
mi
from
Brooklyn, NY
Click here to add this to my saved trials